Evidence map›Paper›PMID 42298882›Full record

ArticleBritish journal of haematology2026

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience.

Hidehiro Itonaga, Takuya Fukushima, Koji Kato, Hiroyuki Muranushi, Masahito Tokunaga, Takayoshi Miyazono, Ayumu Ito, Tetsuya Eto, Youko Suehiro, Takeharu Kato and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Hidehiro ItonagaTransfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.
Takuya FukushimaLaboratory of Hematoimmunology, Department of Clinical Laboratory Sciences, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Ginowan, Japan.
Koji KatoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Hiroyuki MuranushiDepartment of Hematology/Oncology and Transfusion and Hemapheresis Center, Kurashiki Central Hospital, Kurashiki, Japan.ORCID https://orcid.org/0000-0003-3195-2322
Masahito TokunagaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.ORCID https://orcid.org/0000-0003-1296-9006
Takayoshi MiyazonoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Ayumu ItoDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Youko SuehiroDepartment of Hematology and Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan.ORCID https://orcid.org/0009-0003-5690-4228
Takeharu KatoDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Machiko FujiokaDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.ORCID https://orcid.org/0000-0002-1661-8273
Toshiro KawakitaDepartment of Hematology, NHO Kumamoto Medical Center, Kumamoto, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Yasuo MoriHematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-6425-1720
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan.
Kazuho MorichikaDivision of Endocrinology, Diabetes and Metabolism, Hematology, and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan.
Kenji IshitsukaDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
Junya KandaDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Shigeo FujiDepartment of Hematology, Osaka International Cancer Center Institute, Osaka, Japan.ORCID https://orcid.org/0000-0001-5118-7950
ATL working groups of the Japanese Society for Transplantation and Cellular Therapy

Funding

Japan Agency for Medical Research and Development 24ck0106860h0002Japan Society for the Promotion of Science 25K11648SGH Foundation
6 · The paper itself

Abstract

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) offers potentially curative outcomes for adult T-cell leukaemia/lymphoma (ATL), but post-transplant refractory/relapsed (R/R) ATL is associated with poor outcomes. Advances have been made in transplant modalities, novel targeted agents and supportive care; however, it remains unclear whether these advances have improved survival outcomes of post-transplant R/R ATL. To clarify changes in survival after post-transplant R/R, we evaluated the survival outcomes in 1146 patients over a 24-year period, using a nationwide database. The period was divided into three groups: 1999-2010 (early period, as reference), 2011-2016 (middle period) and 2017-2022 (late period). In patients with refractory ATL, multivariate analyses showed no significant difference in overall mortality (OM) after post-transplant refractory in the early and middle periods, but a significantly lower OM in the late period than in the early period (hazard ratio [HR], 0.73 [95% confidence interval, 0.55-0.96]). In patients with relapsed ATL, OM after post-transplant relapse was significantly lower in the middle (HR 0.62 [0.48-0.80]) and late periods (HR 0.68 [0.52-0.90]) than in the early period. Thus, recent advances appear to have contributed to increased opportunities for therapeutic interventions, leading to improved survival outcomes in patients with post-transplant R/R ATL.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia-Lymphoma, Adult T-CellSalvage TherapyAdultAgedFemaleHumansMaleMiddle AgedRecurrenceTransplantation, Homologousadult T‐cell leukaemia/lymphomaallogeneic haematopoietic stem cell transplantationrelapsesalvage therapy

Identifiers

PMID42298882
PMCPMC13462232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.